CYPHERPUNK TECHNOLOGIES Business Summary

Cypherpunk Technologies Inc. (CYPH) operates a dual-core business model that integrates clinical-stage biotechnology development with an aggressive digital asset treasury strategy. The company generates value through its oncology subsidiary, Leap Therapeutics, which focuses on proprietary cancer therapies such as DKN-01, a monoclonal antibody targeting the DKK1 protein, and sirexatamab. Simultaneously, the firm functions as a strategic accumulator of Zcash (ZEC), aiming to secure up to 5% of the total circulating supply to provide institutional-grade exposure to privacy-preserving technologies. Revenue is primarily derived from clinical collaborations and potential future licensing, though current operations are characterized by asset accumulation and R&D investment rather than high-volume transaction fees. Within the market, Cypherpunk Technologies occupies a unique niche as a hybrid "crypto-biotech" entity, competing with biotechnology firms like MacroGenics and Verrica Pharmaceuticals in the oncology space, while mirroring the treasury-first approach of Bitcoin-focused peers like MicroStrategy and Metaplanet. The leadership team is anchored by CEO Douglas Onsi, a veteran executive with over 15 years at the helm of the predecessor entity, Leap Therapeutics, who brings extensive experience in biotech finance and general counsel. In late 2025, the company significantly bolstered its digital asset expertise by appointing Khing Oei, founder of Treasury B.V. and a former Goldman Sachs Special Situations specialist, as Chairman of the Board. He is joined by Chief Investment Officer Will McEvoy, a Principal at Winklevoss Capital, which led a pivotal $58.88 million private placement to fund the company's Zcash strategy. The firm’s strategic direction is further guided by a high-pedigree advisory board including Zcash founder Zooko Wilcox, Electric Coin Company CEO Josh Swihart, and privacy advocate Arjun Khemani, solidifying its ties to the core developers of the Zcash ecosystem.